EBS Emergent BioSolutions Inc.

Emergent BioSolutions Teams Up with Boston Red Sox, Cincinnati Reds, Philadelphia Phillies, and MAPDA to Highlight Importance of Overdose Reversal Medicines on International Overdose Awareness Day

Emergent BioSolutions Teams Up with Boston Red Sox, Cincinnati Reds, Philadelphia Phillies, and MAPDA to Highlight Importance of Overdose Reversal Medicines on International Overdose Awareness Day

-  Organizations Join Together to Raise Awareness of Overdose Reversal Medicines During August 31st Games

GAITHERSBURG, Md., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it is teaming up with the Boston Red Sox, Cincinnati Reds, Philadelphia Phillies, and Mothers Against Prescription Drug Abuse (MAPDA) to highlight the importance of potentially lifesaving overdose reversal medicines on International Overdose Awareness Day 2020. International Overdose Awareness Day is a global event held on August 31 each year that aims to raise awareness of overdose and reduce the stigma of drug-related deaths. Emergent, in collaboration with these teams and MAPDA, will address the importance of accessing overdose reversal medicines through special announcements, videos, and stadium presentations.

“Emergent is committed to doing everything we can to increase awareness, access, and availability of potentially lifesaving overdose reversal medicines,” said Doug White, SVP and devices business unit head at Emergent BioSolutions. “We are proud to team up with the Boston Red Sox, Cincinnati Reds, Philadelphia Phillies, and MAPDA on International Overdose Awareness Day to highlight the important role that overdose reversal medicines play in preparing individuals and families in the event of an accidental opioid overdose. Everyone can take a stand and take action by talking to their doctor or pharmacists about having immediate access to overdose reversal medicines.”

“By increasing awareness about the importance of having immediate access to overdose reversal medicines, we may empower individuals to be prepared in the event of an opioid overdose emergency,” said Mary Bono, former U.S. Congresswoman and chairman and CEO of MAPDA. “MAPDA is honored to stand alongside Emergent, the Boston Red Sox, Cincinnati Reds, and Philadelphia Phillies, to help more individuals know about and access potentially lifesaving medicines to treat opioid overdoses.”

For more information, visit: .

About Emergent BioSolutions

Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through our specialty products and contract development and manufacturing services, we are dedicated to providing solutions that address public health threats. Through social responsibility, we aim to build healthier and safer communities. We aspire to deliver peace of mind to our patients and customers so they can focus on what’s most important in their lives. In working together, we envision protecting or enhancing 1 billion lives by 2030.

About MAPDA

Mothers Against Prescription Drug Abuse (MAPDA) is a nonprofit consumer organization started by three mothers who lost children to prescription drug overdoses. The organization aims to prevent prescription drug abuse before it starts and support individuals in recovery. Mary Bono, a well-known political speaker and consumer advocate, now heads up the organization headquartered in the Washington DC suburbs. Learn more at MAPDA.net.

Media Contact:

Miko B. Neri

Senior Director, Global Communications & Public Affairs

240-631-3392

 

Investor Contact:

Robert G. Burrows

Vice President, Investor Relations

240-631-3280

  

EN
31/08/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Emergent BioSolutions Inc.

 PRESS RELEASE

Emergent BioSolutions Recognizes Several Important Observances to Help...

Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone GAITHERSBURG, Md., Sept. 24, 2025 (GLOBE NEWSWIRE) -- In recognition of several observances in September meant to keep the national opioid poisoning epidemic front and center, Emergent BioSolutions Inc. (NYSE: EBS) today recommitted to its leadership combating the opioid crisis through a multi-faceted approach focused on awareness, education and widespread access to naloxone, including NARCAN® Nasal Spray 4 mg and KLOXXADO® (naloxone...

 PRESS RELEASE

Emergent BioSolutions Secures $29 Million in MCM Product Orders from I...

Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner GAITHERSBURG, Md., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured new purchase orders from an international government partner for a multi-product supply agreement valued at $29 million (USD). The orders span several product offerings within Emergent’s medical countermeasures (MCM) business, including countermeasures for smallpox, anthrax and botulism threats, and reflects the increasing priority governments are placing on defense ...

 PRESS RELEASE

Emergent BioSolutions Secures $17 Million Contract Modification for Or...

Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain GAITHERSBURG, Md., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received a $17 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to supply TEMBEXA® (brincidofovir) oral suspension...

 PRESS RELEASE

Emergent BioSolutions Receives New Contract Modification for ACAM2000®...

Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness GAITHERSBURG, Md., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that a contract modification has been executed in the amount of $56 million to supply ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) to the U.S. government. Deliveries are expected to begin this month. This brings the total projected sales for ACAM2000® vaccine and ancil...

 PRESS RELEASE

Emergent BioSolutions Awarded $30 Million Contract Modification for CY...

Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use GAITHERSBURG, Md., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received a $30 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to supply CYFENDUS® (Anthrax Vaccine Adsorbed...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch